IRWD

#2832
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
3.5 1 USD
-2.50%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
3.50
3.67
Range Annuel
0.56
5.78
Changement quotidien
-2.50%
Changement Mensuel
-16.03%
Evolution sur 6 mois
+1.15%
Changement Annuel
+466.13%
Clôture Précédente
3.6 0
Open
3.6 3
Low
3.5 0
High
3.6 7
Volume
247
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 577.79 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
22.47
ratio cours/chiffre d'affaires
1.85

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

Nouvelles